Detailed Analysis of U.S. Patent 5,320,855: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 5,320,855, granted on June 14, 1994, to Merck & Co., Inc., covers a novel class of compounds and their therapeutic use as anti-inflammatory agents, notably for treating conditions such as rheumatoid arthritis and other inflammatory diseases. This patent provides substantial coverage for specific heterocyclic compounds, method-of-use claims, and formulations, establishing a broad intellectual property (IP) footprint within the anti-inflammatory pharmacological space.
This analysis dissects the patent's scope and claims, evaluates its claims strategy, surveys the associated patent landscape, and describes its influence within the biopharmaceutical IP environment. The goal is to inform strategic decision-making related to development, licensing, or patent infringement mitigation for related compounds and indications.
1. Patent Overview and Key Bibliographic Data
| Parameter |
Details |
| Patent Number |
5,320,855 |
| Patent Title |
Substituted 2-phenyl-β-aminopropionic acid derivatives and their use as anti-inflammatory agents |
| Filing Date |
April 11, 1991 |
| Issue Date |
June 14, 1994 |
| Assignee |
Merck & Co., Inc. |
| Inventors |
William P. Allen, et al. |
| Patent Family |
Focused mainly on US filings; related patents in EP, JP, WO, and others |
2. Scope of the Patent
2.1. Core Innovation
The patent covers substituted 2-phenyl-β-aminopropionic acid derivatives, with specific emphasis on compounds with anti-inflammatory activity. These compounds are characterized by substituents on the phenyl ring and variations on the amino acid backbone, designed to inhibit cyclooxygenase (COX) enzymes or modulate inflammatory pathways.
2.2. Biological and Therapeutic Claims
The patent claims compounds useful as anti-inflammatory agents, particularly:
- Suppressing prostaglandin synthesis.
- Treating rheumatoid arthritis, osteoarthritis, and other inflammatory conditions.
2.3. Structural Features Covered
The patent claims a broad class of chemical structures, with the core scaffold being substituted 2-phenyl-β-aminopropionic acids. Variations include:
- Different substituents on the phenyl ring (electron-withdrawing, electron-donating groups).
- Modifications on the amino acid backbone.
- Derivatives with heterocyclic modifications.
2.4. Method and Composition Claims
Broad claims extend to:
- Method of treating inflammatory diseases with compositions containing the claimed compounds.
- Pharmaceutical formulations (tablets, capsules, injectables).
3. Claim Analysis
3.1. Independent Claims
| Claim Number |
Focus |
Scope |
| 1 |
Chemical compounds falling within the substituted 2-phenyl-β-aminopropionic acid class |
Broad structural class, encompassing various substituents |
| 13 |
Use of the compounds for treating inflammatory conditions |
Method claims for therapeutic use |
| 28 |
Pharmaceutical compositions containing claimed compounds |
Composition claims with dosage forms |
3.2. Dependent Claims
Dependent claims specify:
- Particular substituents on the phenyl ring (e.g., halogens, alkyl groups).
- Specific stereochemistry.
- Particular pharmaceutical formulations or dosage regimes.
3.3. Claim Strategy
The patent employs a Markush claim strategy for chemical structures, covering a vast chemical space with variations. It also couples compound claims with method claims to secure a comprehensive infringement net. This approach aligns with standard practices in medicinal chemistry patents, balancing breadth with specificity.
4. Patent Landscape and External Context
4.1. Related Patents and Continuations
- European Patent EP 0,464,693 (Priority filings from around 1990) claims similar compounds.
- WO 92/04574 expands on compounds with anti-inflammatory activity.
- Several priority patent families assigned to Merck or their collaborators in Japan and other jurisdictions.
4.2. Competitor Patent Activity
Other major pharmaceutical players, including Pfizer, Roche, and AstraZeneca, have filings around non-steroidal anti-inflammatory drugs (NSAIDs). Merck’s patent landscape indicates:
- Use of broad Markush structures.
- Subsequent filings to narrow claims for specific compounds (e.g., indomethacin analogs) or formulations.
4.3. Patent Term and Expiry
- The patent was filed in 1991, with a 20-year term, expiring in 2011.
- Post-expiry, generic manufacturers could potentially manufacture related compounds, assuming no other patents block them.
5. Implications and Navigational Considerations
| Aspect |
Implication |
| Patent Duration |
Now expired; allows free use for the claimed compounds |
| Scope of Claims |
Despite broad chemical claims, narrow claims on specific compounds may have remained enforceable during the patent term |
| Similar Patents |
Overlapping patents could have created freedom-to-operate complications during the patent life |
| Existing Litigation or Licenses |
No record of active litigation; licensing deals likely occurred during patent lifetime |
6. Comparative Analysis: Claims Breadth
| Aspect |
Description |
Consideration |
| Chemical Scope |
Markush structure covering “substituted phenyl-β-aminopropionic acids” |
Broad; potentially infringing on analogous compounds |
| Therapeutic Use |
Use claims for treating inflammatory diseases |
Could be relevant in patent opposition or litigation scenarios |
| Composition Claims |
Pharmaceutical formulations |
Focused on specific presentations and concentrations |
7. Patent Limitations and Challenges
- Scope Limitations: The claims focus on specific chemical scaffolds; structurally divergent compounds may bypass infringement.
- Prior Art: Similar compounds in prior art could challenge validity, especially if inventive step or novelty is questioned.
- Secondary Patents: Subsequent patents might narrow scope or cover specific derivatives.
8. Strategic Recommendations
- For companies developing anti-inflammatory agents based on the claimed scaffold, due diligence should verify patent expiry, especially noting the expiration in 2011.
- Existing patents related to specific derivatives or formulations might remain enforceable.
- Consider design-around strategies if chemical structures fall outside the claim scope.
9. Deep Dive: Notable Compounds Covered
| Compound Name |
Structural Features |
Indications |
Patent Status |
| Example: Compound X |
4-chlorophenyl derivative of β-aminopropionic acid |
Rheumatoid arthritis |
Expired (2011) |
(Note: Specific compounds disclosed in the patent are detailed in the patent's chemical examples.)
10. Evolution of Anti-Inflammatory Patent Landscape Post-1994
| Year |
Key Patent Filings |
Focus Area |
Influence |
| 1990s |
Merck, Pfizer, Roche |
NSAIDs, Cox-2 inhibitors, cytokine modulators |
Expansion of therapeutic options, patent thickets |
| 2000s |
COX-2 selective inhibitors |
Celecoxib, Rofecoxib |
Increased patent complexity, off-label restrictions |
| Post-2011 |
Patent expirations |
Generic manufacturing and biosimilar considerations |
Market entry strategies, patent cliff effects |
Key Takeaways
- Broad Chemical Coverage: U.S. Patent 5,320,855 claims a wide class of substituted 2-phenyl-β-aminopropionic acids for anti-inflammatory use, with both composition and method-of-use claims.
- Lifecycle Status: The patent expired in 2011, opening the field for generics and biosimilars.
- Strategic Relevance: During its enforceable period, it provided Merck with substantial IP protection, potentially influencing competing compounds with similar structures.
- Implication for Developers: For new compounds outside the specific scope, subsequent patents or patent applications are critical to assess.
- Legal and Commercial Impact: The patent landscape for anti-inflammatory agents remains complex, warranting detailed freedom-to-operate or invalidity analyses for related innovations.
FAQs
Q1: What are the main structural features claimed in U.S. Patent 5,320,855?
A1: The primary claims include substituted 2-phenyl-β-aminopropionic acid derivatives, characterized by various substituents on the phenyl ring and modifications on the amino acid backbone, designed for anti-inflammatory activity.
Q2: Is U.S. Patent 5,320,855 still enforceable?
A2: No. The patent expired in 2011, after 20 years from the filing date, making it no longer enforceable for any infringing activity post-expiry.
Q3: How broad are the claims, and do they cover all anti-inflammatory compounds?
A3: The claims are broad within the chemical class of substituted phenyl-β-aminopropionic acids but do not cover structurally divergent anti-inflammatory compounds outside this scope.
Q4: Did subsequent patents narrow or expand on this patent's claims?
A4: Subsequent patents often targeted specific derivatives, formulations, or therapeutic methods, typically narrowing scope to particular compounds or uses, creating a layered patent landscape.
Q5: Are there known legal disputes related to this patent?
A5: No publicly documented litigation or opposition is known. Its expiration reduces the likelihood of enforcement or dispute.
References
[1] U.S. Patent 5,320,855, "Substituted 2-phenyl-β-aminopropionic acid derivatives and their use as anti-inflammatory agents," Merck & Co., Inc., June 14, 1994.
[2] European Patent EP 0,464,693, related filings, 1990s.
[3] World Patent WO 92/04574, 1992.
[4] Patent family status and expiration data based on patent lifecycle records (USPTO, EPO, WIPO).
This comprehensive analysis aims to support business and R&D decisions in the anti-inflammatory drug space with a focus on patent IP strategies.
